Eli Lilly operating profit up marginally by 3%, revenues remains
Eli Lilly and Company has registered operating profit growth of 3 per cent during the first quarter ended March 2013 and its net sales remained flat at $5.6 billion. Worldwide revenue was flat as growth in key products offset lower Zyprexa revenue following patent expirations. Cymbalta revenue increased 19 per cent while Cialis increased 11 per cent. Total revenue in the US increased 2 per cent to $3.137 billion due primarily to increased prices, partially offset by lower volume primarily due to the loss of patent exclusivity for Zyprexa. Total revenue outside the US decreased by 2 per cent to $2.465 billion.